Mylan and Biocon announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.
Biocon jumped 3.7% to Rs.729 on BSE. Mylan and Biocon announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.
The scrip opened at Rs. 705.5 and has touched a high and low of Rs. 734.7 and Rs. 705.5 respectively. So far 1339367(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 14061 crore.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 727 on 01-Jun-2016 and a 52 week low of Rs. 396.5 on 25-Aug-2015. Last one week high and low of the scrip stood at Rs. 727 and Rs. 686.15 respectively.
The promoters holding in the company stood at 60.72 % while Institutions and Non-Institutions held 19.35 % and 17.99 % respectively.
The scrip opened at Rs. 705.5 and has touched a high and low of Rs. 734.7 and Rs. 705.5 respectively. So far 1339367(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 14061 crore.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 727 on 01-Jun-2016 and a 52 week low of Rs. 396.5 on 25-Aug-2015. Last one week high and low of the scrip stood at Rs. 727 and Rs. 686.15 respectively.
The promoters holding in the company stood at 60.72 % while Institutions and Non-Institutions held 19.35 % and 17.99 % respectively.
No comments:
Post a Comment